Archive for the ‘Clinical trials’ Category

Valuing the good, the bad and the ugly

Author: David Kent, 08/29/17

As with all of my posts that relate to anything that might end up being a medical treatment, it is important to be very clear that I am scientist and not a physician.  My comments are my own opinion and based on my experience as a stem cell biologist over the last 10+ years. This…Read more

An ivory tower perspective of the right-to-try movement: We need to balance the equation

Author: Guest, 08/29/17

Patrick Bedford is the Senior Manager of Clinical Translation and Regulatory Affairs at CCRM. He holds a Master’s Degree in Bioethics and Health Law, and a Regulatory Affairs Certificate. Patrick has spent over 11 years applying federal regulations to emerging biotechnologies in Canada. Follow him on LinkedIN. Do desperate times call for desperate measures in the context…Read more

Right Turn: Clinical trials – one solution to unapproved stem cell treatments

Author: Stacey Johnson, 07/14/17

I’ve been thinking about unapproved stem cell treatments a lot recently. First, I read this article that hailed the arrival of stem cell treatments in a small community in western Canada. There were many statements in the article that concerned me, but I only addressed a few major ones in my letter to the editor….Read more

Why do stroke regenerative therapies fail to reach the clinic?

Author: Samantha Payne, 03/07/17

The author of the popular Seven Habits of Highly Effective People book, Steven R. Covery, said “strength lies in differences, not in similarities.” While this may be helpful advice for improving your personal life, researchers are learning that differences in preclinical studies are weakening the ability to translate effective therapies to the clinic. While one…Read more

Learning About Industry from the Insiders at Phacilitate Cell and Gene Therapy World 2017

Author: Nicole Forgione, 02/08/17

In January, I attended Phacilitate’s Cell and Gene Therapy World in Miami, Florida. At this meeting industry leaders from around the world gather to discuss manufacturing, regulation and adoption of cell and gene therapies (C&GT). This was my first industry-focused conference, and it was a great chance to learn the ropes from experienced players in…Read more

Wave of the future: Using anesthesia to detect neurodegeneration

Author: Samantha Payne, 01/03/17

Most people have experienced being put to sleep for a surgical procedure, whether it is relatively minor like the removal of a tooth, or major heart surgery. In fact, every day 60 000 people will undergo general anesthesia in the U.S. You may have noticed a lot of stories sound similar: “I was completely awake…Read more

Crazy for CRISPR!

Author: Sara M. Nolte, 12/05/16

On November 15th, my social media pages exploded with posts and comments regarding the latest news about how the gene-editing ‘CRISPR-Cas9’ technology had been used in the first human patient. The article, published by Nature, was entitled “CRISPR gene-editing tested in a person for the first time.” It described how a group of Chinese scientists…Read more

Insights from CGTW16 – Part 3: Clinical trials, health economics and regulatory affairs

Author: Guest, 12/01/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

Right Turn: The story of scurvy is a poignant cautionary tale for modern medical science

Author: Guest, 11/04/16

Elizabeth (Liz) Csaszar is a development manager for the BridGE team at CCRM. Her areas of interest are cell manufacturing, clinical translation of cell based therapies, and blood cell technologies. Liz obtained her PhD at the University of Toronto, focusing on the strategies to expand and self-renew hematopoietic stem cells in vitro. Liz is interested in…Read more

A peek into a septic shock clinical trial and a patient’s message of hope (TMM2016-Day2)

Author: Hamideh Emrani, 10/27/16

The second day of the Till & McCulloch Meetings (TMM) kicked off with a great talk by Dr. Masayo Takahashi of the Riken Center for Developmental Biology, on the generation of retinal progeny and photoreceptors from iPSCs and ESCs. However, for today, I would like to focus on two different talks. I am sure further…Read more